Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Decreases By 46.6%

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 63,530 shares, a drop of 46.6% from the May 31st total of 119,012 shares. Based on an average trading volume of 126,040 shares, the short-interest ratio is currently 0.5 days. Approximately 0.6% of the company’s shares are sold short.

Institutional Investors Weigh In On Aprea Therapeutics

Large investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in shares of Aprea Therapeutics during the 4th quarter valued at about $40,000. DRW Securities LLC purchased a new position in Aprea Therapeutics in the 4th quarter worth approximately $103,000. Finally, AIGH Capital Management LLC boosted its holdings in Aprea Therapeutics by 174.1% in the 1st quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after acquiring an additional 645,000 shares during the period. Institutional investors and hedge funds own 34.19% of the company’s stock.

Wall Street Analyst Weigh In

APRE has been the subject of several research analyst reports. Oppenheimer started coverage on shares of Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Monday, April 20th. HC Wainwright lowered their price objective on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, Wedbush dropped their price objective on Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.07.

Aprea Therapeutics Trading Up 3.7%

Shares of Aprea Therapeutics stock opened at $0.82 on Tuesday. Aprea Therapeutics has a twelve month low of $0.55 and a twelve month high of $2.22. The stock has a market cap of $10.14 million, a price-to-earnings ratio of -0.53 and a beta of 1.51. The company has a fifty day moving average price of $0.84 and a 200 day moving average price of $0.82.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%. Analysts forecast that Aprea Therapeutics will post -0.84 earnings per share for the current year.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.